JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH

JPMorgan Chase & Co. boosted its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 78.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 213,104 shares of the biopharmaceutical company’s stock after purchasing an additional 93,591 shares during the period. JPMorgan Chase & Co. owned about 0.42% of Theravance Biopharma worth $3,111,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TBPH. Vanguard Group Inc. boosted its stake in shares of Theravance Biopharma by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 6.2% during the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock valued at $11,193,000 after acquiring an additional 44,634 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the third quarter worth $10,611,000. Bank of America Corp DE boosted its position in Theravance Biopharma by 16.5% in the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock worth $5,952,000 after purchasing an additional 76,417 shares during the last quarter. Finally, UBS Group AG boosted its position in Theravance Biopharma by 29.5% in the third quarter. UBS Group AG now owns 514,170 shares of the biopharmaceutical company’s stock worth $7,507,000 after purchasing an additional 117,037 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TBPH shares. TD Cowen boosted their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Finally, Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.33.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $16.02 on Friday. Theravance Biopharma, Inc. has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The business has a 50-day moving average of $17.05 and a 200 day moving average of $16.97. The firm has a market cap of $824.92 million, a P/E ratio of 7.89 and a beta of 0.17.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.